{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:11:26Z","timestamp":1779894686762,"version":"3.53.1"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.13935","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T15:00:58Z","timestamp":1601391658000},"page":"e2013935","source":"Crossref","is-referenced-by-count":13,"title":["Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy"],"prefix":"10.1001","volume":"3","author":[{"given":"Chelsea C.","family":"Pinnix","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian R.","family":"Gunther","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikaela E","family":"Bankston","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Milgrom","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Colorado, Denver"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boyce","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun Ju","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Steiner","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Strati","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaminathan P.","family":"Iyer","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Westin","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simrit","family":"Parmar","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Alma","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouthaina S.","family":"Dabaja","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"issue":"5","key":"zoi200527r1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin\u2019s lymphoma.","volume":"366","author":"Meyer","year":"2012","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi200527r2","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin\u2019s disease.","volume":"21","author":"Aleman","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi200527r3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijrobp.2020.02.635","article-title":"PET guided therapy for early stage Hodgkin lymphoma: are we positive about a negative interim scan?","volume":"107","author":"Bakst","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"zoi200527r4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/978-3-642-83781-4","article-title":"Risk factor adapted treatment of Hodgkin\u2019s lymphoma: strategies and perspectives.","volume":"117","author":"Loeffler","year":"1989","journal-title":"Recent Results Cancer Res"},{"issue":"7","key":"zoi200527r5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma.","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"31","key":"zoi200527r6","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin Lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group.","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16","key":"zoi200527r7","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 Trial.","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"17","key":"zoi200527r8","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma.","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi200527r9","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2009.25.3260","article-title":"Treatment of favorable, limited-stage Hodgkin\u2019s lymphoma with chemotherapy without consolidation by radiation therapy.","volume":"28","author":"Canellos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi200527r10","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"20","key":"zoi200527r11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"27","key":"zoi200527r12","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi200527r13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.meddos.2012.02.003","article-title":"Involved field radiation for Hodgkin\u2019s lymphoma: the actual dose to breasts in close proximity.","volume":"37","author":"Dabaja","year":"2012","journal-title":"Med Dosim"},{"issue":"1","key":"zoi200527r14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","article-title":"Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer.","volume":"79","author":"Feng","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"zoi200527r15","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines.","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"},{"key":"zoi200527r16","doi-asserted-by":"publisher","first-page":"b4606","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort.","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ"},{"issue":"8","key":"zoi200527r17","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1200\/JCO.2008.20.2267","article-title":"Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer.","volume":"28","author":"Tukenova","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi200527r18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ijrobp.2015.02.010","article-title":"Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.","volume":"92","author":"Pinnix","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"zoi200527r19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease.","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"zoi200527r20","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ijrobp.2018.03.003","article-title":"Predictors of hypothyroidism in Hodgkin lymphoma survivors after intensity modulated versus 3-dimensional radiation therapy.","volume":"101","author":"Pinnix","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"zoi200527r21","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"zoi200527r22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/bjc.1995.364","article-title":"Review of survival analyses published in cancer journals.","volume":"72","author":"Altman","year":"1995","journal-title":"Br J Cancer"},{"issue":"3","key":"zoi200527r23","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of normal tissue complication probability models in the clinic.","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"zoi200527r24","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.ijrobp.2010.09.054","article-title":"Thyroid V30 predicts radiation-induced hypothyroidism in patients treated with sequential chemo-radiotherapy for Hodgkin\u2019s lymphoma.","volume":"82","author":"Cella","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"zoi200527r25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/asheducation-2011.1.323","article-title":"Late effects in the era of modern therapy for Hodgkin lymphoma.","volume":"2011","author":"Hodgson","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"zoi200527r26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1053\/j.seminhematol.2016.05.008","article-title":"Hodgkin lymphoma: late effects of treatment and guidelines for surveillance.","volume":"53","author":"Ng","year":"2016","journal-title":"Semin Hematol"},{"issue":"26","key":"zoi200527r27","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma.","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi200527r28","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.radonc.2018.08.017","article-title":"Comparison of butterfly volumetric modulated arc therapy to full arc with or without deep inspiration breath hold for the treatment of mediastinal lymphoma.","volume":"129","author":"Starke","year":"2018","journal-title":"Radiother Oncol"},{"key":"zoi200527r29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1748-717X-9-94","article-title":"Dosimetric advantages of a \u201cbutterfly\u201d technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin\u2019s lymphoma.","volume":"9","author":"Voong","year":"2014","journal-title":"Radiat Oncol"},{"issue":"3","key":"zoi200527r30","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.prro.2013.07.015","article-title":"Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: impact on normal tissue dose.","volume":"4","author":"Charpentier","year":"2014","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"zoi200527r31","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.ijrobp.2011.05.015","article-title":"Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin\u2019s lymphoma.","volume":"82","author":"Paumier","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"zoi200527r32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ijrobp.2016.10.004","article-title":"Secondary breast cancer risk by radiation volume in women with Hodgkin lymphoma.","volume":"97","author":"Conway","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"zoi200527r33","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.","volume":"129","author":"van Nimwegen","year":"2017","journal-title":"Blood"},{"issue":"3","key":"zoi200527r34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma.","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2770978\/pinnix_2020_oi_200527_1600357368.24575.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T15:01:00Z","timestamp":1601391660000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2770978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.13935","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]}}}